Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Aug;99(8):e138-41.
doi: 10.3324/haematol.2014.104976. Epub 2014 Apr 24.

Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis

Santiago Montes-Moreno  1 , Ana Batlle  2 , Sonia González de Villambrosía  3 , Beatriz Sánchez-Espiridión  4 , Laura Cereceda  4 , Eva González-Barca  5 , Noelia Purroy  6 , Emilia Pardal  7 , Alejandro Martín  8 , Carlos Grande  9 , Francisco Mazorra  10 , Andrés Insunza  11 , Cristina Quero  12 , David Aguiar  13 , Miguel Angel Cruz  14 , Antonio Rueda  15 , Marta Llanos  16 , José Gómez Codina  17 , Francisco Ramón García Arroyo  18 , Dolores Caballero  8 , Eulogio Conde  3 , Andrés López  6 , Mariano Provencio  19 , Miguel Piris  10
Affiliations
Clinical Trial

Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis

Santiago Montes-Moreno et al. Haematologica. 2014 Aug.
No abstract available

Keywords: biological classification; diffuse large B-cell lymphoma; dose-dense therapies; high-dose.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
(A, B) Overall survival (OS) and progression-free survival (PFS) Kaplan Meier estimates according to advanced age (>60 years old). Patients under 60 years old had a probability of OS and PFS over 85% in the median follow-up time. (C, D). IPI risk stratification into Low, Low-intermediate, High-intermediate and High IPI was predictive for PFS (P < 0.05) but not OS. Patients with low IPI risk had an excellent outcome with survival probabilities over 90% in the median follow-up time. However no differences were found among Low-intermediate, High-intermediate and High IPI risk. (C, D). OS and PFS Kaplan Meier estimates according to cell of origin classification: ABC type DLBCL prognosis was significantly improved when compared with the R-CHOP 21 treated control cohort (P <0.005), while GCB type DLBCL prognosis was not altered. Patients treated with high-dose and dose-dense therapies had an OS and PFS equivalent for both GCB and ABC subtypes (81% vs. 84% for OS and 79% vs. 75% for PFS). (E, F). miRNA expression signatures were found of prognostic value for OS (P log rank = 0.05) and PFS (P log rank 0.04). Cases with low miRNA score had a 90% ± 4 % PFS probability compared to 74% ± 4 % for cases with high miRNA score.
See this image and copyright information in PMC

References

    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2008
    1. Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97(5):758–65 - PMC - PubMed
    1. Karlin L, Coiffier B. Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions. Onco Targets Ther. 2013;6:289–96 - PMC - PubMed
    1. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 2013;369(18):1681–90 - PMC - PubMed
    1. Vose JM. Intensified chemotherapy for diffuse large B-cell lymphomas. Lancet. 2011;378(9806):1828–9 - PubMed

MeSH terms

Supplementary concepts